Premium
High‐dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant
Author(s) -
Kalaycio Matt,
Pohlman Brad,
Kuczkowski Elizabeth,
Rybicki Lisa,
Andresen Steve,
Sobecks Ronald,
Bolwell Brian
Publication year - 2006
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2006.00581.x
Subject(s) - medicine , busulfan , etoposide , surgery , cyclophosphamide , incidence (geometry) , lymphoma , autologous stem cell transplantation , chemotherapy , stem cell , cumulative incidence , transplantation , physics , biology , optics , genetics
The non‐relapse mortality of autologous stem cell transplant is low enough that the procedure has been extended to older patients with non‐Hodgkin's lymphoma. We treated 537 non‐Hodgkin's lymphoma patients with high‐dose chemotherapy consisting of busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplant. Sixteen patients were identified who died of pulmonary complications at a five‐year incidence of 3.6%. Risk factors for pulmonary mortality included older age and lower baseline D CO and FEV 1 . We conclude that high‐dose busulfan is associated with pulmonary mortality after autologous transplant, particularly in older patients.